This is an old revision of this page, as edited by Boghog(talk | contribs) at 06:16, 6 February 2020(consistent citation formatting; templated cites). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 06:16, 6 February 2020 by Boghog(talk | contribs)(consistent citation formatting; templated cites)
Phase 2 clinical trials in patients with colorectal cancer, osteosarcoma and Ewing's sarcoma are complete.[2][3] Merck has since discontinued development.[4]
^Clinical trial number NCT00551213 for "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)" at ClinicalTrials.gov